Patrick Harris, MD1, Tasnia Matin, MD2, Nan Zhang, MS3, Malik Talha, MD3
1University of Alabama at Birmingham, Birmingham, AL; 2Medical University of South Carolina, Charleston, SC; 3Mayo Clinic, Scottsdale, AZ
Introduction: Crohn’s Disease (CD) is a chronic inflammatory condition, primarily of the gastrointestinal tract with an increasing incidence and prevalence worldwide. In clinical practice, gastroenterologists are often faced with challenges in evaluating disease activity, severity, and prognosis to guide appropriate management of CD. We studied the association between serum albumin level and the rate of active clinical disease in CD patients seen at a tertiary care Inflammatory Bowel Disease (IBD) referral center.
Methods: We designed a retrospective cohort study using adult patients ( > 18 years) with CD followed for at least one year at University of Alabama at Birmingham (UAB) IBD center by a single trained IBD specialist between 2014-2018. Serum albumin levels were divided into: low mean serum albumin (< =3.2 mg/dL) vs. appropriate mean serum albumin ( > 3.2 mg/dL). Clinical disease activity was measured using the Harvey-Bradshaw index (HBI). Active disease was defined as HBI score of 8 or higher. Poisson Regression Models (GPR) for Rate Data were used to estimate partially adjusted and fully adjusted incidence rate ratios (IRR) of active clinical disease among CD patients. We also examined IRRs for serum albumin level as a continuous variable.
Results: In this single IBD practice at UAB, 269 patients with CD had albumin drawn at initial visit and serially at each subsequent visit. Poisson regression model adjusted for age, gender, race, duration of disease, steroid use, smoking and Crohns location demonstrated that CD patients with a low mean serum albumin during clinical observation were approximately 1.5 times more likely to have active clinical disease during observation (IRR 1.49, 95%CI 1.04-2.15, P=0.032) compared to those with a serum albumin level of > 3.2 mg/dL. The adjusted model with serum albumin as a continuous variable demonstrated that with every unit (0.1 mg/dL) reduction in mean serum albumin, there was 30% higher likelihood of active Crohns in clinic (IRR 1.30, 95%CI 1.02-1.66, P=0.037).
Discussion: Lower mean serum albumin during clinical observation is associated with a higher likelihood of active clinical disease among CD patients. Whether interventions designed to correct or increase serum albumin stores / levels in these patients would be beneficial remains to be examined.
Citation: Patrick Harris, MD; Tasnia Matin, MD; Nan Zhang, MS; Malik Talha, MD. P1423 - ASSOCIATION BETWEEN SERUM ALBUMIN LEVELS AND THE RATE OF ACTIVE CROHN’S DISEASE IN PATIENTS SEEN AT A TERTIARY CARE IBD CENTER. Program No. P1423. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.